Lv7
5000 积分 2022-09-14 加入
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
1个月前
已完结
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
1个月前
已完结
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
1个月前
已完结
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
1个月前
已完结
First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial
1个月前
已完结
Sozinibercept Combination Therapy for Neovascular Age-related Macular Degeneration: Phase 2b Study Subgroup Analysis by Lesion Type
2个月前
已关闭
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials
2个月前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
3个月前
已完结
皖公网安备34019202002308
